SAN FRANCISCO, Aug. 07, 2020 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (NASDAQ:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it has added two new independent directors to its board who bring deep commercial and strategic experience to the company: Suzanne Sawochka Hooper, the former executive vice president and general counsel of Jazz Pharmaceuticals, and Duke Rohlen, the CEO and managing partner of Ajax Health.
Eidos is developing acoramidis (formerly AG10) as a potentially best-in-class treatment option for ATTR patients.
Ms. Hooper and Mr. Rohlen will replace departing board members Rajeev Shah and Eric Aguiar, M.D.
“I feel grateful to be working with Suzanne and Duke as we continue to execute our Phase 3 clinical trial and prepare for commercialization. I admire their collective accomplishments greatly and look forward to learning from them. I'd also like to thank Eric and Raj for their fine service in shepherding Eidos to this point. In just a few years we've been able to create a remarkable company and that is poised to help patients at scale,” said Eidos CEO and founder, Neil Kumar, Ph.D.
Ms. Hooper brings more than 25 years of executive and corporate leadership experience and sophisticated legal expertise to the Eidos board. As executive vice president and general counsel at Jazz Pharmaceuticals from March 2012 through February 2019, she played an active role in the management and strategic development of the company during a period of substantial growth. Prior to joining Jazz, Ms. Hooper was a partner in the Cooley LLP law firm, representing a broad range of companies and investors in the life sciences industry and working with boards of directors and senior management teams on complex legal and strategic matters, including M&A. Ms. Hooper has been a member of the Board of Directors of NGM Biopharmaceuticals, Inc. since 2018.
"I'm excited by …
Full story available on Benzinga.com